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Glecaprevir/Pibrentasvir in Patients
With Hepatitis C Virus Genotype 1 or
4 and Past Direct-Acting Antiviral
Treatment Failure
Fred Poordad,1 Stanislas Pol,2 Armen Asatryan,3 Maria Buti,4 David Shaw,5 Christophe Hezode,6 Franco Felizarta,7
Robert W. Reindollar,8 Stuart C. Gordon,9 Stephen Pianko,10 Michael W. Fried,11 David E. Bernstein,12 Joel Gallant,13
Chih-Wei Lin,3 Yang Lei,3 Teresa I. Ng,3 Preethi Krishnan,3 Sarah Kopecky-Bromberg,3 Jens Kort,3 and Federico J. Mensa3
Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options. MAGELLAN-1 Part 2 was a randomized, open-label,
phase 3 study to evaluate the efﬁcacy and safety of ribavirin (RBV)-free glecaprevir and pibrentasvir (G/P; 300 mg/
120 mg) in patients with chronic HCV and past VF on at least one NS3/4A protease and/or NS5A inhibitorcontaining therapy. Patients with compensated liver disease, with or without cirrhosis, and HCV genotype (GT) 1, 4,
5, or 6 were randomized 1:1 to receive 12 or 16 weeks of G/P. The primary endpoint was sustained virological response
(SVR) at 12 weeks posttreatment (SVR12). Among 91 patients treated, 87 had GT1 and 4 had GT4 infection. SVR12
was achieved by 89% (39 of 44) and 91% (43 of 47) of patients who received 12 and 16 weeks of G/P, respectively.
Virological relapse occurred in 9% (4 of 44) of patients treated with 12 weeks of G/P; there were no relapses with 16
weeks of treatment. Past treatment history with one class of inhibitor (protease or NS5A) had no impact on SVR12,
whereas past treatment with both classes of inhibitors was associated with lower SVR12 rate. The most common
adverse event (AE) was headache (10% of patients), and there were no serious AEs assessed as related to study drugs
or AEs leading to discontinuation. Conclusion: Sixteen weeks of G/P treatment achieved a high SVR12 rate in patients
with HCV GT1 infection and past failure to regimens containing either NS5A inhibitors or NS3 protease inhibitors.
(HEPATOLOGY 2018;67:1253-1260)

M

ost currently available direct-acting antiviral (DAA) treatment regimens for chronic
infection with hepatitis C virus (HCV)
include nonstructural protein 5A (NS5A) inhibitors
and are highly effective. However, patients that have
virological failure (VF) with NS5A inhibitor-containing
regimens commonly develop resistance-associated substitutions (RASs) that decrease the efﬁcacy of subsequent retreatment.(1-3) Additionally, in contrast to
treatment-emergent substitutions in NS3, which disappear within the ﬁrst year posttreatment, RASs in NS5A

can persist for several years.(4,5) Therefore, effective
retreatment of patients who have had VF on NS5A
inhibitor-containing regimens has been challenging,
and retreatment options for this population are currently
limited.(6,7) Addition of ribavirin (RBV) and/or
extended treatment durations using combinations of
three to four DAAs have been strategies utilized to provide retreatment options for patients(2,8-12); however,
clinical data from large studies are not available for most
of these regimens, and sustained virological response
(SVR) rates have generally been suboptimal. Recently,

Abbreviations: AEs, adverse events; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransferase; CI, conﬁdence interval; DAA, direct-acting antiviral; DCV, daclatasvir; DSV, dasabuvir; EC50, half-maximal effective concentration;
GLE, glecaprevir; G/P, glecaprevir and pibrentasvir; GT, genotype; HCV, hepatitis C virus; kPa, kilopascals; LDV, ledipasvir; LLOD, lower limit of
detection; LLOQ, lower limit of quantiﬁcation; NS5A, nonstructural protein 5A; OBV, ombitasvir; PI, protease inhibitor; PIB, pibrentasvir; PTV/r,
ritonavir boosted paritaprevir; RASs, resistance-associated substitutions; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR, sustained virological
response; SVR12, sustained virological response at posttreatment week 12; TE, transient elastography; VEL, velpatasvir; VF, virological failure.
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the three DAA ﬁxed-dose combination of sofosbuvir
(SOF)/velpatasvir (VEL)/voxilaprevir demonstrated an
overall 96% SVR12 rate in patients with past NS5A
inhibitor experience.(13,14) However, the use of SOF
may not be suitable for important subpopulations, such
as those with advanced renal disease.(15) Therefore,
effective retreatment options using RBV-free DAA
combinations without SOF, which retain antiviral activity against common NS5A RASs, are needed.
Glecaprevir (GLE) is an HCV NS3/4A protease
inhibitor (PI), and pibrentasvir (PIB) is an NS5A
inhibitor. They have been coformulated (G/P) in clinical trials for the treatment of all six major HCV genotypes. GLE has demonstrated in vitro half-maximal
effective concentration (EC50) values 5 nanomolar
across all major HCV genotypes (GTs), and has <5fold loss of activity against most GT1 RASs (such as
those at positions 36, 56, 80, 155, and 156) that may
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be selected during treatment with currently available
NS3/4A PIs.(16,17) PIB has EC50 values 5 picomolar
across all major HCV GTs and has demonstrated minimal loss in potency against known NS5A RASs (such
as those at positions 24, 28, 30, 31, 58, 92, and 93),
including GT1a Y93H (6.7-fold increase in EC50),(18)
which substantially reduces susceptibility to other
NS5A inhibitors, such as VEL (609-fold increase in
EC50), ledipasvir (LDV; 3,294-fold increase in EC50),
and daclatasvir (DCV; 1,600-fold increase in
EC50).(19) This suggests that G/P could provide an
effective retreatment regimen, including for patients
with past experience with NS5A inhibitor-containing
regimens.
MAGELLAN-1 Part 1 was a phase 2 dose-ranging
study that evaluated the efﬁcacy and safety of GLE
and PIB for 12 weeks, with or without RBV, in GT1infected patients with past treatment failure on DAA
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regimens containing an NS5A inhibitor and/or NS3/
4A PI with or without NS5B inhibitors. The modiﬁed
intent-to-treat (modiﬁed intent-to-treat analysis
excludes patients that failed because of nonvirological
reasons) sustained virological response (SVR) at 12
weeks posttreatment (SVR12) rate was 95%, regardless
of RBV coadministration, and was not affected by past
treatment regimen or presence of baseline RASs.(20)
In this study, MAGELLAN-1 Part 2, the efﬁcacy
and safety of RBV-free G/P for 12 or 16 weeks was
planned to be evaluated in patients with chronic HCV
GT1, 4, 5, or 6 infection, including those with compensated cirrhosis, and past treatment failure on NS3/4A
protease and/or NS5A inhibitor-containing regimens.

Patients and Methods
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FIG. 1. MAGELLAN-1, Part 2 study design. Patients were
randomized 1:1 and stratiﬁed by HCV GT (1 or 4) and past
treatment experience (NS5A inhibitor-na€ıve or -experienced) to
receive either 12 or 16 weeks of once-daily G/P (300 mg/
120 mg). All patients had past VF, virological failure to at least
one HCV treatment regimen containing an approved NS3/4A
protease and/or NS5A inhibitor allowed by study protocol.
Patients were followed for 24 weeks posttreatment to monitor
safety and SVR.


STUDY OVERSIGHT
All patients signed informed consent, and the study
was conducted in accord with the International Conference on Harmonization guidelines and the ethics set
forth by the Declaration of Helsinki.

STUDY DESIGN
MAGELLAN-1 (NCT02446717) Part 2 was a
randomized, open-label, multicenter, phase 3 study
that assessed the efﬁcacy and safety of G/P in patients
with chronic HCV GT1 or GT4 infection, including
those with compensated cirrhosis, who had past failure
on at least one NS3/4A protease and/or NS5A
inhibitor-based regimen. The trial design schematic is
shown in Fig. 1, and a ﬂow diagram showing patient
recruitment and enrollment is depicted in Supporting
Fig. S1. Patients were randomized 1:1 to receive either
12 or 16 weeks of all-oral coformulated G/P (without
RBV; GLE was discovered by AbbVie and Enanta).
G/P was dosed as 3 pills (100 mg/40 mg each) for a
total dose of 300 mg/120 mg once-daily.

PATIENT POPULATION
Patients were screened at 31 sites in Australia,
France, Spain, the United Kingdom, and the United
States (including Puerto Rico). Patients at least 18
years old (no upper limit) were eligible if they had
chronic HCV GT1, 4, 5, or 6 infection with HCV
RNA >1,000 IU/mL at screening. HCV genotype
and subtype were assessed with the Versant HCV
Genotype Inno LiPA Assay, version 2.0 or higher, or

Sanger sequencing of the NS5B region if indeterminate initially by LiPA. Patients had to have past VF
failure to an approved DAA-containing regimen that
included an NS5A inhibitor (limited to DCV, LDV,
or ombitasvir [OBV]) and/or NS3/4A PI (limited to
paritaprevir, simeprevir [SIM], asunaprevir, telaprevir,
or boceprevir). NS5B inhibitors (SOF or dasabuvir
[DSV]) could have been present in any past treatment
regimen, and patients could have had failure to multiple past regimens. Patients with sequential exposures
to multiple regimens (i.e., PI-containing regimen followed by an NS5A inhibitor-containing regimen) were
considered to have past experience to both. Median
time since patients’ last previous VF is reported in the
Supporting Information. Patients could have compensated cirrhosis (Child-Pugh score of 6 or less) or no
cirrhosis. Absence of cirrhosis (e.g., METAVIR score
3, Ishak score 4) was determined by liver biopsy
within 24 months before (or during) screening, transient elastography (TE; FibroScan) score of <12.5 kilopascals (kPa) within 6 months before (or during)
screening, or a screening FibroTest score of 0.48 and
an aspartate aminotransferase (AST) to platelet ratio
index (APRI) <1. Presence of cirrhosis was determined by past histological diagnosis of cirrhosis on
liver biopsy (e.g., METAVIR [or equivalent] score of
>3 [including 3/4], Ishak score of >4), past TE
(FibroScan) score of 14.6 kPa, or a screening
FibroTest score of 0.75 and an APRI >2. Patients
with indeterminate FibroScan were required to have
liver biopsy and indeterminate FibroTest or conﬂicting
FibroTest, and APRI scores were required to have TE

1255

POORDAD ET AL.

or liver biopsy to determine cirrhosis status. Complete
inclusion and exclusion criteria are included in Supporting Table S1.

ASSESSMENT OF EFFICACY,
SAFETY, AND VIROLOGICAL
RESISTANCE
The primary endpoint was the percentage of
patients who achieved SVR at 12 weeks after the last
dose of study drug (SVR12 deﬁned as HCV RNA
below the lower limit of quantiﬁcation [LLOQ; 15
IU/mL]). Secondary endpoints included the percentage of patients with on-treatment VF and relapse.
Plasma samples were collected at screening, days 1 and
3, weeks 1 and 2, 4, 6, 8, 10, 12, and 16 (only for
patients treated for 16 weeks), and at post-treatment
weeks 2, 4, 8, 12, and 24. In the event of premature
discontinuation, a plasma sample was taken at the time
of discontinuation. Plasma HCV-RNA levels were
determined using the Roche (Basel, Switzerland)
AmpliPrep COBAS TaqMan real-time reverse transcriptase PCR assay v2.0 with a high pure system. The
lower limit of detection (LLOD) and LLOQ of HCV
RNA for this assay were both 15 IU/mL.
Safety analyses were conducted on adverse events
(AEs), vital signs, physical examinations, electrocardiograms, and laboratory tests and included all patients
receiving at least 1 dose of study drug. Treatmentemergent AEs were collected from study drug initiation until 30 days after study drug discontinuation.
Each AE was classiﬁed using the MedDRA version
19.0 system organ class and preferred term, and, subsequently, causality of each AE with respect to study
drugs was determined by the study physician. Changes
from baseline in laboratory tests and vital sign measurements were also assessed.
Next-generation sequencing was used with a 15%
detection threshold to identify the presence of baseline
substitutions in NS3 and NS5A relative to subtypespeciﬁc reference sequences. The amino acid positions
included in the analysis of baseline substitutions were
36, 56 (GT1a only), 155, 156, and 168 in NS3, and
24, 28, 30, 31, 58, 92, and 93 in NS5A. Positions
known to commonly harbor polymorphisms that do
not confer signiﬁcant in vitro resistance to GLE or
PIB (e.g., Q80 in NS3) were not included in the analysis in order to focus analysis on relevant resistance
positions. Treatment-emergent substitutions in NS3
and NS5A were analyzed for patients who had VF.
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STATISTICAL ANALYSES
The study did not test a formal hypothesis. The percentage of patients who achieved SVR12 in each arm
was summarized with a two-sided 95% conﬁdence
interval (CI) using the Wilson score method for binomial proportions. The difference in SVR12 rates
between treatment arms was analyzed using the
stratum-adjusted Mantel-Haenszel proportion with a
continuity correction for variance, adjusted for each
randomization stratum. Statistical analyses were performed using SAS software.

Results
BASELINE PATIENT
DEMOGRAPHICS
A total of 122 patients were screened between January 12, 2016 and March 14, 2016; 31 patients failed
screening, and 91 with HCV GT1 (n 5 87) or GT4
(n 5 4) infection were enrolled and treated. No
patients with GT5 or GT6 infection were enrolled.
Patients were randomized (1:1): 44 patients received
12 weeks of G/P and 47 were treated for 16 weeks.
Demographics across the two treatment arms were
generally well balanced. A majority of patients were
male (70%), white race (76%), and had subtype 1a
HCV (74%); 30% (27 of 91) of patients had compensated cirrhosis (34% and 26% of patients in the 12and 16-week arms, respectively). In both the 12- and
16-week treatment arms, approximately one third of
patients had past experience with an NS3/4A PI alone,
an NS5A inhibitor alone, or both (Table 1). Nineteen
(21%) patients had previously taken SOF 1 LDV
(NS5A inhibitor-only experienced) as their only past
treatment. Twenty (22%) patients had past treatment
with more than one course of DAA-containing
regimen.
Across both treatment arms, 30% of patients had no
baseline substitutions in either NS3 or NS5A, whereas
66% (29 of 44) and 61% (27 of 44) had substitution(s)
in NS5A in the 12- and 16-week treatment arms,
respectively (Table 1). Seventeen percent (15 of 88) of
patients had substitutions in NS3 at baseline. Baseline
substitutions in both NS3 and NS5A had similar prevalence in the 12- and 16-week treatment arms. In
patients with past experience with only NS5A inhibitors (NS3/4A PI-na€ıve), 84% (27 of 32) had baseline
substitutions in NS5A; none of the patients had baseline NS3 substitutions. In contrast, 27% (8 of 30) of
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TABLE 1. Baseline Demographics and Clinical Characteristics
Characteristic
Male, n (%)
White race, n (%)
Black race, n (%)
Age, median years (range)
BMI, median kg/m2 (range)
IL28B non-CC genotype, n (%)
HCV RNA, median log10 IU/mL (range)
Compensated cirrhosis, n (%)
HCV subtype*, n (%)
1a
1b
1c
4
Previous DAA regimen class†, n (%)
NS3/4A PI only (NS5A inhibitor-na€ıve)
NS5A inhibitor only (PI-na€ıve)
N3/4A PI 1 NS5A inhibitor
Past DAA treatment response, n (%)
On-treatment failure
Virological relapse
Time since last treatment, median (range) months
Presence of key baseline substitutions‡, n (%)
None
NS3 only
NS5A only
NS3 1 NS5A

12 Weeks
N 5 44

16 Weeks
N 5 47

31 (70)
34 (77)
9 (20)
57 (22-67)
28 (21-41)
38 (86)
6.1 (4.7-7.2)
15 (34)

33 (70)
35 (75)
11 (23)
56 (36-70)
29 (20-52)
42 (89)
6.3 (4.7-7.1)
12 (26)

35 (80)
8 (18)
—
1 (2)

32
11
1
3

14 (32)
16 (36)
14 (32)

13 (28)
18 (38)
16 (34)

14 (32)
30 (68)
19 (2-94)

13 (28)
34 (72)
10 (3-61)

13 (30)
2 (5)
24 (55)
5 (11)

13
4
23
4

(71)
(23)
(2)
(6)

(30)
(9)
(52)
(9)

*Genotype and subtype determined by the Versant HCV Genotype Inno LiPA Assay, version 2.0 or higher, or Sanger sequencing of
NS5B if LiPA result was indeterminate.
†
SOF (NS5B inhibitor) could be included in any previous treatment regimen.
‡
Sequencing data were available in 44 patients in each arm; percentages are based on N 5 44; substitutions detected by nextgeneration sequencing using 15% detection threshold at positions 36, 56 (GT1a only), 155, 156, and 168 in NS3, and 24, 28, 30, 31,
58, 92, and 93 in NS5A. Abbreviation: BMI, body mass index.

patients with past experience with both classes of
inhibitors had baseline substitutions in both NS3 and
NS5A, whereas 3% (1 of 30) and 50% (15 of 30) of
those patients had baseline substitutions in NS3 or
NS5A alone, respectively. Detailed information on
prevalence of baseline substitutions is shown in Supporting Tables S2 and S3.

EFFICACY
Patients treated with 12 weeks of G/P had an
SVR12 rate of 89% (39 of 44; 95% CI, 76-95), with
one on-treatment VF and four relapses, whereas those
treated for 16 weeks had an SVR12 rate of 91% (43 of
47; 95% CI, 80-97), with four on-treatment VFs
(Table 2). All 4 patients with GT4 infection achieved
SVR12; details for the 9 GT1 patients that had VF
(four relapses and ﬁve on-treatment failures) are shown
in Supporting Table S4. Of the 5 patients with ontreatment failure, all 5 ended their past treatment
within 1 year of initiating G/P, with a median time
since last treatment of 4.6 (range, 2.6-8.7) months.

Median time from past treatment failure to retreatment with G/P for the entire enrolled population was
17 (range, 2.2-94) months, whereas those with relapse
had a median time since last treatment of 26 (range,
5.7-60) months.
Patients with past treatment experience with only
NS3/4A PIs (NS5A inhibitor-na€ıve) had 100%
SVR12 regardless of treatment duration. For patients
with past experience with only NS5A inhibitors,
SVR12 rates were 88% (14 of 16; 95% CI, 64-97) and
94% (17 of 18; 95% CI, 74-99) for 12 and 16 weeks of
treatment, respectively. For patients with past experience with both classes of inhibitors (NS3/4A and
NS5A), SVR12 rates were 79% (11 of 14; 95% CI,
52-92) and 81% (13 of 16; 95% CI, 57-93) in those
treated for 12 and 16 weeks, respectively. Three of six
patients with past experience to both classes of inhibitors that did not achieve SVR12 had on-treatment VF.
Patients with no baseline substitutions in either
NS3 or NS5A, or with substitutions in NS3 alone,
had a 100% SVR12 rate. Patients with baseline substitutions in NS5A alone had SVR12 rates of 83% (20 of
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TABLE 2. SVR and Efficacy Outcomes
Event, n/N
(%, CI*)
Overall SVR12
On-treatment VF
Virological relapse
Past DAA class
NS3/4A PI only
NS5A inhibitor only
NS3/4A PI 1 NS5A inhibitor
Past DAA regimen
SOF/LDV
SOF 1 SIM
OBV/PTV/r 6 DSV 6 RBV
Other DAA† 1 pegIFN/RBV
Multiple past regimens
Other‡
Baseline substitutions§
None
NS3 only
NS5A only
NS3 1 NS5A

12 Weeks
N 5 44

16 Weeks
N 5 47

39/44 (89; 76-95)
1/44 (2)
4/44 (9)

43/47 (91; 80-97)
4/47 (9)
0/47

14/14 (100; 79-100)
14/16 (88; 64-97)
11/14 (79; 52-92)

13/13 (100; 77-100)
17/18 (94; 74-99)
13/16 (81; 57-93)

8/9 (89)
—
5/5 (100)
16/17 (94)
4/5 (80)
6/8 (75)

9/10 (90)
3/3 (100)
5/6 (83)
16/16 (100)
4/6 (67)
6/6 (100)

13/13 (100; 77-100)
2/2 (100)
20k/24 (83; 64-93)
4#/5 (80)

13/13 (100; 77-100)
4/4 (100)
22¶/23 (96; 79-99)
1**/4 (25)

*CI calculated at 95% with the normal approximation to the binomial distribution.
†
Includes DCV, telaprevir, or boceprevir.
‡
Any other combination of DAA regimens allowed by study protocol.
§
Sequencing data were available in 44 patients in each arm; substitutions detected by next-generation sequencing using 15% detection
threshold at positions 36, 56 (GT1a only), 155, 156, and 168 in NS3, and 24, 28, 30, 31, 58, 92, and 93 in NS5A.
k
Three relapses and one on-treatment failure.
¶
One on-treatment failure.
#
One relapse.
**Three on-treatment failures.
Abbreviation: pegIFN/RBV, pegylated interferon plus ribavirin.

24; 95% CI, 64-93) and 96% (22 of 23; 95% CI, 7999) with 12 and 16 weeks of G/P treatment, respectively. Among these patients, three of four VFs in the
12-week arm were relapses; there were no relapses in
patients treated for 16 weeks (Table 2). Of those
patients with baseline substitutions in both NS3 and
NS5A, three of nine (33%) had on-treatment VF in
the 16-week arm of G/P treatment. These 3 patients
all failed their last previous treatment regimen within 9
months of starting G/P. Furthermore, all 3 of these
patients had past experience with NS5A, NS5B, and
PIs, including OBV/paritaprevir/ritonavir and DSV
(OBV/PTV/r [ritonavir boosted paritaprevir] 1 DSV)
with or without additional regimens (Supporting Table
S4). SVR12 rates by all past DAA regimens are listed
in Table 2.

SAFETY, AEs, AND LABORATORY
ABNORMALITIES
The majority of AEs were classiﬁed as mild (65%),
and no patient prematurely discontinued study drug
because of AEs (Table 3). There were three treatment-
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emergent serious AEs reported in the study: a gastrointestinal viral infection, back pain, and wound infection; none were assessed by the study investigators as
related to the study drugs. Headache was the only AE
reported in 10% of patients. There were no clinically
signiﬁcant alanine aminotransferase (ALT), AST, or
bilirubin elevations in the study (Table 3). Safety was
comparable between those with and without cirrhosis.
Three patients experienced non-treatment-emergent
AEs of hepatocellular carcinoma, all detected during
the posttreatment period (37, 71, and 105 days after
last treatment), and all considered not related to the
study drugs by investigators.

Discussion
In this study, RBV-free coformulated G/P for 16
weeks was safe and demonstrated 100% and 94%
SVR12 rates, with no virological relapses, in patients
with past failure to NS3/4A PI only– and NS5A
inhibitor only–containing regimens, respectively.
Those with past experience with both of these classes
of inhibitors had a lower SVR12 rate.
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TABLE 3. AEs and Laboratory Abnormalities*
Event, n (%)
Adverse events
Any AE
Grade 1 (mild) AE, n/N (%)
Serious AE†
Serious AE related to study drugs
AEs leading to study drug discontinuation
AEs occurring in  10% of patients
Headache
Laboratory abnormalities
ALT‡, Grade 3 (>5 3 ULN)
AST‡, Grade 3 (>5 3 ULN)
Total bilirubin, Grade 3 (>3 3 ULN)
Hemoglobin, Grade 3 (<8 g/dL)

12 Weeks
N 5 44

16 Weeks
N 5 47

33 (75)
24/33 (73)
1 (2)
0
0

32 (68)
18/32 (56)
2 (4)
0
0

6 (14)

11 (23)

0
0
0
0

0
0
0
0

*Grades as per National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.0.
†
Serious AEs included gastrointestinal viral infection, back pain,
and wound infection.
‡
Postnadir increase in grade to Grade 3.

NS5A inhibitor-na€ıve patients with past failure with
NS3/4A PI–containing regimens (i.e., boceprevir, telaprevir, and SIM) had 100% SVR12 rate, regardless of
treatment duration. The median time from past treatment failure to retreatment with G/P in the enrolled
population was 17 months, and the majority of patients
had no substitutions in NS3 at baseline. This is consistent with the observation that RASs in NS3 selected by
past PI therapy are generally undetectable within 1 year
posttreatment,(21) making successful retreatment of this
patient population more likely over time.
Patients with past failure to NS5A inhibitorcontaining regimens (but PI-na€ıve) had a 94% (17 of
18) SVR12 rate after 16 weeks of G/P treatment, compared to 88% (14 of 16) when treated for 12 weeks.
Consistent with these results, patients with baseline
substitutions in NS5A alone had a 96% (22 of 23)
SVR12 rate when treated for 16 weeks, compared to
83% (20 of 24) when treated for 12 weeks. Among
those with chronic HCV GT1 infection and past failure with NS5A inhibitor-containing regimens, the
lack of virological relapses in patients treated for 16
weeks (compared with one relapse in the 12-week
treatment arm), indicates that a 16-week duration may
be required to minimize virological relapse. With only
4 GT4-infected patients enrolled in this study, all
whom achieved SVR12, the optimal treatment duration could not be identiﬁed in this population.
The presence of NS5A substitutions at baseline was
observed in the majority of patients with past NS5A
inhibitor experience (50 of 64; 78%); however, there
was no consistent pattern of substitutions associated

with VF to G/P. Treatment failure in this study was
generally associated with the presence of baseline
NS5A substitutions in conjunction with NS3 substitutions. All 3 patients that had on-treatment VF after
past exposure to both NS3/4A and NS5A classes of
inhibitors and had detectable combinations of Y56H
and D168A/E substitutions in NS3 at baseline, in
addition to substitutions in NS5A. All 3 patients were
randomized to the 16-week treatment arm, had past
failure to OBV/PTV/r 6 DSV with or without additional regimens, and had recent failure on their previous course of DAA therapy (within 9 months of
enrollment). These factors explain the presence of
multiple baseline NS3 substitutions that decrease susceptibility to GLE in these patients.(22) Thus, these
data suggest that patients with past experience to
OBV/PTV/r 6 DSV 6 RBV, or those with multiple
past courses of therapy that included NS3/4A protease
and NS5A classes of inhibitors, may have an increased
rate of VF.
One limitation of this study was the small number of
GT4 patients available for enrollment, which prevented
a robust assessment of efﬁcacy in this genotype.
Another limitation was the lack of patients with failure
to more recently approved DAA regimens, such as
elbasvir/grazoprevir and SOF/VEL; these regimens
were approved after study initiation. However, SOF/
LDV- or DCV-containing regimens are currently the
most commonly prescribed HCV treatment regimens
for patients with GT1 infection; 27% and 24% of
patients enrolled in this study were SOF/LDV- and
DCV-experienced, respectively. Another limitation
was the small number of patients enrolled with compensated cirrhosis. Finally, few patients were enrolled
with past failure to both an NS3/4A PI and NS5A
inhibitor, because these patients are less common given
the high efﬁcacy of current generation regimens. In this
study, patients with past experience to both classes of
DAAs had lower SVR12 rates, at 79% and 81% after
12 or 16 weeks of G/P treatment, respectively. In contrast, 30 of 31 (97%) patients with past experience to
either NS3/4A protease or NS5A inhibitor DAA classes achieved SVR12 after 16 weeks of G/P treatment.
In this study, the RBV-free combination of G/P
was safe and well tolerated, regardless of treatment
duration (12 or 16 weeks), and there were no AEs that
led to study drug discontinuation. Furthermore, G/P
demonstrated a low rate of serious AEs (none of which
were assessed as related to study drugs), and there were
no clinically relevant elevations in ALT, AST, or total
bilirubin.
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In summary, patients with NS3/4A PI experience
alone had a 100% SVR12 rate regardless of 12- or 16week treatment duration, whereas 16-week treatment
duration may be required for patients with NS5A
inhibitor experience alone (94% SVR12 with no virological relapses). Those with past experience with both
of these DAA classes had lower SVR12 rates. Overall,
RBV-free G/P demonstrated high SVR12 rates in
patients with past failure with approved NS3/4A PIs
or NS5A inhibitors.
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